Sign inCreate account

Report workspace tools

NCT03384524WITHDRAWNanonymous

A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema

Sponsor

Source record

Andrew Moshfeghi, MD, MBA

Phase

Source record

Phase I/II

Modality

AI-normalized

small molecule

Target

AI-normalized

Diabetic Macular Edema (DME)

Indication / condition

AI-normalized

Diabetic Macular Edema

Intervention

Source record

Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG, Placebo

Source & freshness

Source record

NCT ID

NCT03384524

Original source

ClinicalTrials.gov

Source last updated

Apr 01, 2019

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03384524

Title

A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema

Sponsor

Andrew Moshfeghi, MD, MBA

Status

WITHDRAWN

Phase

Phase I/II

Condition raw

Diabetic Macular Edema

Condition normalized

Diabetic Macular Edema

Modality raw

Diabetic Macular Edema

Modality normalized

small molecule

Target raw

Diabetic Macular Edema (DME)

Target normalized

Diabetic Macular Edema (DME)

Interventions

Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG, Placebo

Public preview

Source record

The BEAT DME Study aimed to evaluate the efficacy of a combination therapy (Bromocriptine, Metoprolol, and Tamsulosin) in treating non-central DME. The study was designed to provide proof of concept for future phase III trials, focusing on a systems pharmacology approach to address complex retinal diseases.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03384524

Status

WITHDRAWN

Phase

Phase I/II

Sponsor

Andrew Moshfeghi, MD, MBA

Executive brief

Investment-Ready Snapshot

The BEAT DME Study aimed to evaluate the efficacy of a combination therapy (Bromocriptine, Metoprolol, and Tamsulosin) in treating non-central DME. The study was designed to provide proof of concept for future phase III trials, focusing on a systems pharmacology approach to address complex retinal diseases.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 01, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03384524

Indication

Diabetic Macular Edema

Modality

small molecule

Target

Diabetic Macular Edema (DME)

Intervention

Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.